Take a trial of UK to unlock this pageFind out more

Relative Strength (%)
Volume Change (%)
10d v 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
Margin of Safety (beta)
Screens Passed 1
Balance Sheet · Income Statement · Cashflow Financial Summary
Year End 31st Dec 2009 2010 2011 2012 2013 2014 TTM 2015E 2016E CAGR / Avg
Revenue $m
Operating Profit $m
Net Profit $m
EPS Reported $
EPS Normalised $
EPS Growth %
PE Ratio x
Operating Margin %
Op. Cashflow ps $
Capex ps $
Free Cashflow ps $
Last ex-div: 13th Aug, paid: 14th Sep more... Dividends
Dividend ps $
Dividend Growth %
Dividend Yield %
Dividend Cover x
Balance Sheet
Cash etc $m
Working Capital $m
Net Fixed Assets $m
Net Debt $m
Book Value $m
Average Shares m
Book Value ps $ +1.8%

FINANCIAL BRIEF: For the nine months ended 30 September 2015, AstraZeneca plc revenues decreased 7% to $18.31B. Net income increased 30% to $2.02B. Revenues reflect Western Europe segment decrease of 21% to $3.9B, United States segment decrease of 8% to $6.9B. Net income reflects Other income and expense increase from $256M to $1.19B (income), R & D -Restructuring Costs decrease of 14% to $180M (expense). Dividend per share remained flat at $0.90. more »

Health Trend
Bankruptcy Risk
  Earnings Manipulation Risk
Magic Formula Score
Other Ratios
Leverage (ttm) Total Ex Intang
Gross Gearing %
Net Gearing %
Cash / Assets %
Recent History
Latest interim period (ended 30th Sep '15) vs. prior year
Sales Growth %
EPS Growth %
3yr Compound Annual Growth Rate
Sales Growth %
EPS Growth %
DPS Growth %

Broker Forecasts
31st Dec 2015
31st Dec 2016

Price Target: $71.8
(+5.41% above Price)
Net Profit EPS DPS Net Profit EPS DPS
Est. Long Term Growth Rate: +1.4% ($) (¢) (¢) ($) (¢) (¢)
Consensus Estimate
1m Change
3m Change
31 brokers Broker Consensus Trend
Broker Recommendations for AstraZeneca
Recommendation:Strong SellSellHoldBuyStrong Buy
No. of Analysts: 1 6 10 9 7

Named Brokers and Analysts
Jefferies Jeffrey Holford , Credit Suisse Matthew Weston , SEB Equities , Leerink Partners LLC Seamus Fernandez , BERNSTEIN Tim Anderson , Danske Markets Martin Parkhøi Mattias Häggblom Thomas Bowers , Seymour Pierce , Panmure Gordon Mike Mitchell , Natixis Philippe Lanone Jean-Jacques Le Fur , Mirabaud Securities Nicholas Turner , Swedbank Markets Johan Unnerus , Nordea Markets Erik Hultgaard , Societe Generale Justin Smith , Pareto Securities AS Yilmaz Mahshid , Berenberg Alistair Campbell , DZ Bank , Oddo Securities Sebastien Malafosse , Helvea SA Odile Rundquist , Kepler Cheuvreux Fabian Wenner, PhD , Charles Stanley Rae Ellingham , Shore Capital Stockbrokers Brian White , Bryan Garnier Eric Le Berrigaud , Morningstar, Inc. Damien Conover , Day by Day Valérie GASTALDY , Landesbank Baden-Wuerttemberg Timo Kuerschner , Liberum Naresh Chouhan , Baader Helvea Equity Research Odile Rundquist ,

Profile Summary

AstraZeneca PLC (AstraZeneca) is a global biopharmaceutical company. The Company discovers, develops and commercializes prescription medicines for Cardiovascular and Metabolic diseases; Oncology; Respiratory, Inflammation and Autoimmunity, Infection, Neuroscience and Gastrointestinal. The Company's medicines include Crestor for managing cholesterol levels; Seloken/Toprol-XL for hypertension, heart failure and angina; Onglyza for Type 2; Iressa for lung cancer; Faslodex for breast cancer; Zoladex for prostate and breast cancer; Pulmicort for asthma; Symbicort for asthma and COPD (chronic obstructive pulmonary); Nexium for acid-related diseases; Seroquel XR for schizophrenia, bipolar disorder and depressive disorder, and Synagis for RSV (respiratory syncytial virus), a respiratory infection in infants. The Company's pipeline includes 133 projects, of which 118 are in the clinical phase of development. AstraZeneca operates in over 100 countries.

Directors: Pascal Soriot (CEO) 56, Marc Dunoyer (CFO) 62, Fiona Cicconi (EVP) , Sean Bohen (EVP) , Ruud Dobber (EVP) , Paul Hudson (EVP) , Bahija Jallal (EVP) , Mark Mallon (EVP) , Luke Miels (EVP) , Menelas Pangalos (EVP) , Leif Johansson (NEC) , Cornelia Bargmann (NED) , Genevieve Berger (NED) 60, Ann Cairns (NED) 58, Marcus Wallenberg (NED) 59,

No. of Employees: 57,500 No. of Shareholders: 100,371

Last Annual December 31st, 2014
Last Interim September 30th, 2015
Incorporated June 17, 1992
Public Since September 21, 2007
Shares in Issue 1,263,837,596
Free Float 1.26bn (99.7%)

Address - Legal Department 2 Kingdom Street, LONDON, W2 6BD, United Kingdom
Web http://www.astrazeneca.com/
Phone +44 20 73045000
Contact Thomas Larsen (IR Contact Officer)
Auditors KPMG LLP

AZN Share Price Performance AZNQuote
10.5  0.2%
Traded 3:38pm · Minimum 15 min delayed · NMS: 0.500k

Latest AZN News Announcements (delayed)

Upcoming AZN Events

Recent ↓
Thursday 13th August, 2015
Dividend For AZN.L
Wednesday 12th August, 2015
Dividend For AZN
Wednesday 12th August, 2015
Dividend For AZN.BA
Thursday 30th July, 2015
Q2 2015 AstraZeneca PLC Earnings Call
Thursday 30th July, 2015
AstraZeneca PLC Split For AZN.BA
Thursday 30th July, 2015
Q2 2015 AstraZeneca PLC Earnings Release
Friday 24th July, 2015
AstraZeneca PLC Split For AZN
Tuesday 23rd September, 2014
AstraZeneca PLC at EBD Group BioPharm America
Wednesday 13th August, 2014
Dividend For AZN.BA
Wednesday 13th August, 2014
Dividend For AZN
Wednesday 13th August, 2014
Dividend For AZN.L
Thursday 31st July, 2014
Q2 2014 AstraZeneca PLC Earnings Call
Thursday 31st July, 2014
Q2 2014 AstraZeneca PLC Earnings Release
Thursday 19th June, 2014
AstraZeneca PLC at Citi European Healthcare Conference
Tuesday 3rd June, 2014
AstraZeneca PLC at Jefferies Global Healthcare Conference
Monday 2nd June, 2014
AstraZeneca PLC ASCO Analyst Briefing
Wednesday 21st May, 2014
AstraZeneca PLC To Discuss The Key New Phase IIb Data In Severe Asthma Conference Call
Tuesday 6th May, 2014
AstraZeneca PLC Conference Call to provide an update on Company's Strategy

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2015.

Should you buy AZN

Access AZN Analytics Now!

Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis